Vienna, June 2024. We are pleased to announce the formation of our Scientific Advisory Board (SAB), which includes leading experts in the field of cancer research and small molecule development. This milestone marks a significant step forward in our mission to demonstrate how our platform screening approach for protein-protein interaction inhibitors and our pipeline molecules can improve the lives of cancer patients.
Anna Quattropani, PhD
VP Chemisty Anavo Tx, Expert in medicinal chemistry
Anna brings over 20 years of experience in medicinal chemistry and drug discovery, with a strong track record of advancing clinical candidates through to Phase 2/3. She has invented small molecules for neurodegenerative diseases and reproductive health. Her expertise spans targeted protein degradation, enzyme inhibition, GPCR modulation, and protein-protein interactions across various therapeutic areas. Currently SVP of Chemistry and Non-Clinical Development at Anavo Therapeutics, Anna holds 48 patents in oral and CNS small molecule drug discovery, medicinal chemistry, and synthetic organic chemistry.
Jürgen Moll, PhD
Ex-Boehringer Ingelheim, Expert in cancer drug development
Jürgen is a distinguished expert in cancer research and preclinical drug development, focusing on cancer cell targeting and immuno-oncology with small molecules, antibodies, and nanobodies. He has advanced oncology drugs at big pharma companies like Novartis, Pfizer, and Sanofi, as well as biotech spin-offs. Jürgen has held leadership roles at Sanofi, Boehringer-Ingelheim, and Nerviano Medical Sciences. An international consultant, SAB member, and lecturer, he holds a PhD in Biochemistry from the University of Basel and a degree in Microbiology from the University of Bayreuth.
Peter Nussbaumer, PhD
KHAN/LDC, Expert in medicinal chemistry
Peter has over 30 years of industry experience in drug discovery. Before joining the LDC, he held key roles in medicinal chemistry at Sandoz and Novartis, most recently as Executive Director and Senior Unit Head of Chemistry at Novartis Institutes for Biomedical Research. He has managed numerous drug discovery projects and coordinated interdisciplinary and international teams. Peter has published extensively in peer-reviewed journals, is a co-inventor on several patents, and holds a PhD in organic chemistry from the University of Technology, Vienna.
Prof. Richard Moriggl, PhD
Co-founder, Expert in STAT/JAK Biology
Prof. Moriggl is a leading expert in STAT biology, with significant contributions to understanding STAT3/5 signaling in normal and cancer cells. He was a Professor for Functional Cancer Genomics at Vetmeduni Vienna from 2014 to 2022 and has been a successful PI for 17 years, overseeing personnel, funding, and scientific management. As director of the Ludwig Boltzmann Institute for Cancer Research for 14 years, he shaped a successful research program and managed an annual budget of up to €2.5 million.
RIANA Therapeutics 